BioNotebook: Juno's $134m Series B more than 3 VC deals combined
This article was originally published in Scrip
Executive Summary
Juno Therapeutics continues to astound the biotechnology industry and the 2013 startup hasn't even reported any human clinical trial results, but the Seattle, Washington-based company has raised an eye-popping $310m in venture capital financing since its launch in December.